DelveInsight's 'Follicular Lymphoma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...

Lisocabtagene maraleucel has been granted FDA approval for the treatment of patients with relapsed/refractory follicular lymphoma. Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, ...

Monjuvi, Revlimid and Rituxan improved progression-free survival among adults with relapsed or refractory follicular lymphoma, topline research showed.

Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made based on histology, disease burden and patient symptoms. The general approach should be a ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Incyte’s previously disclosed phase 3 win in relapsed or refractory follicular lymphoma (R/R FL) sent the company racing to file an expansion bid for its Monjuvi (tafasitamab) by year-end.

It is uncommon for simple cysts to lead to rupture, torsion, or hemorrhaging, which can cause more severe symptoms. Severe symptoms may be signs of more than a follicular cyst. Immediate medical ...

The final diagnosis was diffuse large B-cell lymphoma (DLBCL) of follicular center origin involving the omentum, bilateral adnexal masses, and left ovary, with gastric implants. A repeat ...

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular ... in Europe are diagnosed with ...

A Canadian woman with stage 4 cancer says she ignored signs of the disease because she believed them to be “eczema-related.” ...